Details for Patent: 9,241,948

Which drugs does patent 9,241,948 protect, and when does it expire?

Patent 9,241,948 protects INFUGEM and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 9,241,948

Title:	Ready to be infused gemcetabine solution
Abstract:	A large volume infusion dosage form of gemcitabine, comprising a stable large volume solution of gemcitabine or its pharmaceutically acceptable salt in an aqueous vehicle filled in a large volume infusion container, wherein the solution is ready-to-be-infused.
Inventor(s):	Kumar; Samarth (Vadodara, IN), Kane; Prashant (Vadodara, IN), Namdeo; Alok B. (Vadodara, IN), Bhowmick; Subhas B (Vadodara, IN), Ganorkar; Kirti (Mumbai, IN)
Assignee:	Sun Pharmaceutical Industries Ltd. (Mumbai, IN)
Application Number:	13/871,438
Patent Claim Types: see list of patent claims	Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 9,241,948

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sun Pharm	INFUGEM	gemcitabine hydrochloride	SOLUTION;INTRAVENOUS	208313-001	Jul 16, 2018		DISCN	Yes	No			Y
Sun Pharm	INFUGEM	gemcitabine hydrochloride	SOLUTION;INTRAVENOUS	208313-002	Jul 16, 2018		DISCN	Yes	No			Y
Sun Pharm	INFUGEM	gemcitabine hydrochloride	SOLUTION;INTRAVENOUS	208313-003	Jul 16, 2018		DISCN	Yes	No			Y
Sun Pharm	INFUGEM	gemcitabine hydrochloride	SOLUTION;INTRAVENOUS	208313-004	Jul 16, 2018		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 9,241,948

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
India	1334/MUM/2012	Apr 27, 2012

International Family Members for US Patent 9,241,948

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013261012
Brazil	112014026334
Canada	2871061
China	104254319